ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC

Head and neck squamous cell carcinoma (HNSCC) accounts for 3–5% of all tumor types and remains an unmet medical need with only two targeted therapies approved to date. ErbB3 (HER3), the kinase-impaired member of the EGFR/ErbB family, has been implicated as a disease driver in a number of solid tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarado, Diego, Ligon, Gwenda F., Lillquist, Jay S., Seibel, Scott B., Wallweber, Gerald, Neumeister, Veronique M., Rimm, David L., McMahon, Gerald, LaVallee, Theresa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5517012/
https://www.ncbi.nlm.nih.gov/pubmed/28723928
http://dx.doi.org/10.1371/journal.pone.0181356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5517012/
https://www.ncbi.nlm.nih.gov/pubmed/28723928
http://dx.doi.org/10.1371/journal.pone.0181356

Ejemplares similares